Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vectibix with Chemoradiotherapy in Irresectable Esophageal Cancer
NCT01262183Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2011
- Primary completion
- Apr 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in esophageal cancer, sponsored by Radboud University Medical Center. Started Jan 2011; status: terminated.
02
Drugs
panitumumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT01262183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262183.